PMID- 35993803
OWN - NLM
STAT- MEDLINE
DCOM- 20230120
LR  - 20230413
IS  - 1468-3083 (Electronic)
IS  - 0926-9959 (Print)
IS  - 0926-9959 (Linking)
VI  - 37
IP  - 2
DP  - 2023 Feb
TI  - Impact of blood involvement on efficacy and time to response with mogamulizumab 
      in mycosis fungoides and Sezary syndrome.
PG  - 311-316
LID - 10.1111/jdv.18549 [doi]
AB  - BACKGROUND: Cutaneous T-cell lymphomas (CTCL) are rare types of non-Hodgkin 
      lymphoma, which present in skin. Mycosis fungoides (MF) and Sezary syndrome (SS) 
      are subtypes which make up two-thirds of all CTCL cases. The phase 3 MAVORIC 
      study (NCT01728805) compared mogamulizumab to vorinostat in MF and SS patients, 
      with post hoc data showing a trend for higher efficacy in mogamulizumab-treated 
      patients as baseline blood tumour burden increases. OBJECTIVES: The aim of this 
      study was to use updated post hoc analyses in order to examine the efficacy of 
      mogamulizumab and vorinostat in MF patients when stratified by baseline blood 
      involvement and to determine what factors affect time-to-global and time-to-skin 
      response to inform clinical follow-up. METHODS: Post hoc analyses were carried 
      out using data from MAVORIC. Overall response rate (ORR), progression-free 
      survival (PFS) and time-to-next-treatment (TTNT) data were used to assess 
      efficacy in patients with MF. Time-to-global response (TTR) was examined by 
      disease subtype, by blood involvement in MF patients, and time-to-skin response 
      was examined by blood involvement in MF patients. RESULTS: Numerically superior 
      results were seen for ORR, PFS and TTNT in mogamulizumab-treated patients with MF 
      compared with vorinostat, with a trend for outcomes improving with increasing 
      baseline blood class. Statistically significant results for mogamulizumab 
      compared with vorinostat were seen for MF B1 pts for PFS (8.43 vs. 2.83 months, 
      p = 0.003) and TTNT (11.9 vs. 3.13 months, p = 0.002), and for MF B2 pts for ORR 
      (46.2 vs. 9.1 months, p = 0.033). CONCLUSIONS: In mogamulizumab-treated MF 
      patients, ORR and PFS were seen to improve with increasing blood involvement, 
      which led to improved TTNT. TTR was more predictable for mogamulizumab-treated MF 
      patients with blood involvement, and skin response may take longer than 
      previously reported in some patients.
CI  - (c) 2022 The Authors. Journal of the European Academy of Dermatology and 
      Venereology published by John Wiley & Sons Ltd on behalf of European Academy of 
      Dermatology and Venereology.
FAU - Beylot-Barry, Marie
AU  - Beylot-Barry M
AUID- ORCID: 0000-0001-6150-1229
AD  - University of Bordeaux, UMR 1312 INSERM, Bordeaux, France.
AD  - Dermatology Department, CHU Bordeaux, Bordeaux, France.
FAU - Booken, Nina
AU  - Booken N
AD  - Department of Dermatology and Venereology, University Hospital Hamburg-Eppendorf, 
      Hamburg, Germany.
FAU - Weishaupt, Carsten
AU  - Weishaupt C
AUID- ORCID: 0000-0003-1195-2106
AD  - Department of Dermatology, University Hospital of Muenster, Muenster, Germany.
FAU - Scarisbrick, Julia
AU  - Scarisbrick J
AD  - University Hospital Birmingham, Birmingham, UK.
FAU - Wu, Wende
AU  - Wu W
AD  - Kyowa Kirin, Inc, Princeton, New Jersey, USA.
FAU - Rosen, Jan-Paul
AU  - Rosen JP
AD  - Kyowa Kirin International, Buckinghamshire, UK.
FAU - Medley, Michael C
AU  - Medley MC
AUID- ORCID: 0000-0001-8663-5821
AD  - Kyowa Kirin International, Buckinghamshire, UK.
LA  - eng
GR  - Kyowa Kirin/
PT  - Clinical Trial
PT  - Journal Article
DEP - 20220830
PL  - England
TA  - J Eur Acad Dermatol Venereol
JT  - Journal of the European Academy of Dermatology and Venereology : JEADV
JID - 9216037
RN  - YI437801BE (mogamulizumab)
RN  - 58IFB293JI (Vorinostat)
SB  - IM
MH  - Humans
MH  - *Lymphoma, T-Cell, Cutaneous/pathology
MH  - *Mycosis Fungoides/drug therapy/pathology
MH  - *Sezary Syndrome/drug therapy/pathology
MH  - *Skin Neoplasms/drug therapy/pathology
MH  - Vorinostat/therapeutic use
PMC - PMC10087984
COIS- MBB has performed a consulting or advisory role for Kyowa Kirin and Recordati. 
      She has also received travel expenses from Kyowa Kirin and Recordati. NB has 
      received honoraria from Kyowa Kirin and Recordati. She has also performed a 
      consulting or advisory role for Kyowa Kirin. She has also received travel 
      expenses from Kyowa Kirin, Recordati and Takeda. CW has received honoraria from 
      Bristol Meyer Squibb, Kyowa Kirin, and Merck Sharp and Dohme. He has also 
      received travel expenses from Bristol Meyer Squibb. He has also performed an 
      advisory role for Bristol Meyer Squibb, Kyowa Kirin, and Merk Sharp and Dohme. He 
      has also performed a work group leadership role for Nationale 
      Versorgungskonferenz Hautkrebs (NVKH). JS has received consulting fees from 
      Codiak, Kyowa Kirin, Takeda, Therakos, Recordati and Helsinn. She also has 
      performed an advisory role for Affimed Therapeutics and Codiak. WW, J-PR and MCM 
      are employees of Kyowa Kirin, Inc.
EDAT- 2022/08/23 06:00
MHDA- 2023/01/18 06:00
PMCR- 2023/04/11
CRDT- 2022/08/22 09:33
PHST- 2022/02/28 00:00 [received]
PHST- 2022/08/05 00:00 [accepted]
PHST- 2022/08/23 06:00 [pubmed]
PHST- 2023/01/18 06:00 [medline]
PHST- 2022/08/22 09:33 [entrez]
PHST- 2023/04/11 00:00 [pmc-release]
AID - JDV18549 [pii]
AID - 10.1111/jdv.18549 [doi]
PST - ppublish
SO  - J Eur Acad Dermatol Venereol. 2023 Feb;37(2):311-316. doi: 10.1111/jdv.18549. 
      Epub 2022 Aug 30.